Catalog No.
Product Name
Application
Product Information
Citations
-
HSD17B13 Inhbitor
HSD17B13-IN-34 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily deployed in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition offers valuable insights into therapeutic strategies targeting dysregulated steroid metabolism in hepatic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-56 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is crucial for investigating the role of HSD17B13 in various hepatic and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition makes it a valuable tool for advancing research in liver pathology and associated cardiovascular conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-51 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as drug-induced liver injury (DILI). Its specific targeting of HSD17B13 positions it as a critical tool for investigating metabolic and cardiovascular disease pathways. -
17BHSD13 Inhibitor
HSD17B13-IN-105 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase 13 (17BHSD13), exhibiting an IC50 value of 0.036 μM and notable selectivity against 17BHSD4 with an IC50 of 31.5 μM. This compound is valuable for research applications targeting liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its specificity and potent inhibition profile make it a significant tool for studying the biochemical pathways involved in these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-48 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action on HSD17B13 makes it a crucial tool for research into the pathophysiology and therapeutic targeting of these conditions. -
HSD17B13 Inhbitor
HSD17B13-IN-89 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This reagent is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), offering valuable insights into the role of HSD17B13 in hepatic metabolism and disease progression. Its specificity and efficacy make it a critical tool for studying the pathophysiology of metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-82 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as in metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-82 is useful for studying drug-induced liver injury (DILI) and its underlying mechanisms. -
AKR1C3 Inhibitor
Indomethacin methylester is a selective inhibitor of AKR1C3, exhibiting an IC50 of 5.67 μM. This compound is particularly relevant for studying its role in prostate cancer research, where it may aid in elucidating the mechanisms underlying tumor progression and therapeutic resistance. Its specificity for AKR1C3 offers potential insights into targeting this enzyme for cancer treatment strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-71 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research targeting liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, HSD17B13-IN-71 can aid in investigations of drug-induced liver injury (DILI), making it a crucial tool in related biological studies. -
HSD17B13 Inhibitor
HSD17B13-IN-104 is a potent and selective inhibitor of HSD17B13, exhibiting an IC50 of 2.5 nM. This compound effectively modulates hepatic lipid metabolism by targeting the SREBP-1c/FAS signaling pathway, thereby reducing hepatic lipid accumulation. HSD17B13-IN-104 holds potential for advancing research on metabolic dysfunction-associated steatohepatitis and related conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-95 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), with an IC50 value for estradiol of less than 0.1 μM. This compound is useful in the investigation of nonalcoholic fatty liver disease and other metabolic disorders associated with altered steroid hormone metabolism. Its ability to effectively modulate HSD17B13 activity makes it a valuable tool for research into the biological mechanisms underlying liver function and related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-72 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic interventions and mechanisms underlying these conditions. Its high specificity makes it an important tool for elucidating the biological pathways associated with steroid metabolism. -
HSD17B13 Inhbitor
HSD17B13-IN-24 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the understanding of metabolic pathways and potential therapeutic targets in liver disorders. Its high specificity makes it a valuable tool for investigating the role of HSD17B13 in various biological contexts. -
HSD17B13 Inhibitor
HSD17B13-IN-55 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, it may support research into drug-induced liver injury (DILI), providing insights into its mechanisms and potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-61 is a specific inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is intended for research into liver-related conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as various metabolic and cardiovascular diseases. Its high potency makes it a valuable tool for investigating the role of HSD17B13 in these disease contexts. -
HSD17B13 Inhbitor
HSD17B13-IN-90 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases, specifically targeting HSD17B13, with an IC50 of less than 0.1 μM for estradiol. This compound is employed in research related to nonalcoholic fatty liver disease (NAFLD), providing insights into the role of HSD17B13 in lipid metabolism and liver function. Its potent inhibitory activity makes it a valuable tool for investigating the biological effects of steroid hormone modulation in various pathological contexts. -
17β-HSD Inhibitor
HSD17B13-IN-21 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its application in research could provide insight into the mechanisms underlying liver-related metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-12 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. This compound is valuable for studying liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted inhibition offers insights into the biochemical pathways associated with these health issues. -
HSD17B13 Inhibitor
HSD17B13-IN-54 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in various pathologies, including liver diseases, metabolic disorders, and cardiovascular conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a useful tool for studying drug-induced liver injury (DILI). -
PROTAC
PTOTAC HSD17B13 degrader 1 is a PROTAC designed to selectively target and promote the degradation of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13). This compound consists of a specific ligand for HSD17B13, a linker based on tert-Butyl 5-bromoisoindoline-2-carboxylate, and a ligand for an E3 ubiquitin ligase, enabling effective ubiquitination and subsequent proteasomal degradation of the target protein. PTOTAC HSD17B13 degrader 1 is a valuable tool for studying HSD17B13 functions and has potential applications in therapeutic development and protein regulation research. -
HSD17B13 Inhibitor
HSD17B13-IN-96 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value for estradiol of less than 0.1 μM. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its effectiveness in modulating HSD17B13 activity provides valuable insights into the biological pathways involved in liver metabolism and pathology. -
HSD17B13 Inhbitor
HSD17B13-IN-25 is a specific inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound plays a significant role in the study of nonalcoholic fatty liver disease (NAFLD) by modulating steroid metabolism and fatty liver progression. Its application in preclinical research facilitates a deeper understanding of HSD17B13's involvement in lipid metabolism and liver pathology. -
HSD17B13 Inhibitor
HSD17B13-IN-79 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-79 serves as an important tool for research aimed at understanding the role of HSD17B13 in these pathological conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-91 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol ranging between 0.1 μM and 0.5 μM. This compound is utilized in research contexts focusing on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and cardiovascular diseases. Additionally, it is relevant for studying drug-induced liver injury (DILI), making it a valuable tool for understanding the role of HSD17B13 in various pathological conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-77 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research related to liver diseases and metabolic disorders, providing insight into the role of HSD17B13 in various physiological and pathological processes. Its application may enhance understanding of steroid metabolism and its implications in health and disease. -
HSD17B13 Inhibitor
HSD17B13-IN-20 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a crucial role in the modulation of estrogen metabolism and is particularly relevant in the study of liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. HSD17B13-IN-20 provides valuable insights into the therapeutic targeting of HSD17B13 for the treatment and understanding of hepatic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-68 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases and metabolic disorders, providing insights into potential therapeutic targets and mechanisms of action in these conditions. Its potency and specificity make it a useful tool for research in endocrinology and metabolic pathways. -
HSD17B13 Inhibitor
HSD17B13-IN-64 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 may provide insights into therapeutic strategies for these conditions. -
17β-HSD10 Inhibitor
ESC1002755 is a selective inhibitor of 17β-HSD10, exhibiting an IC50 of 19 nM and demonstrating non-competitive inhibition against the cofactor NADH. This compound shows minimal cytotoxicity in HEK293 cells at a concentration of 50 μM, making it a promising tool for studies related to Alzheimer’s disease and hormone-dependent cancers, including prostate, bone, and colorectal cancer. Research applications include exploring the enzymatic mechanisms and therapeutic interventions associated with these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-11 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting potent activity with an IC50 of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver pathologies, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its role in metabolic and cardiovascular research also supports its utility in exploring potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-38 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound plays a significant role in the regulation of steroid metabolism and has potential implications in the study of liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Researchers can utilize HSD17B13-IN-38 to explore its impact on cardiovascular diseases and related metabolic pathways. -
17β-HSD Inhibitor
HSD17B13-IN-23 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), particularly in relation to nonalcoholic steatohepatitis (NASH). Its capacity to modulate HSD17B13 activity makes it a valuable tool for investigating the biochemical pathways involved in hepatic lipid metabolism and related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-88 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤0.1 μM for estradiol. This compound selectively modulates steroid hormone metabolism and has significant implications for research in metabolic disorders and liver diseases. Its ability to influence estradiol levels makes it a valuable tool for studying hormone-related pathways and therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-99 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound demonstrates significant potential for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Researchers can utilize HSD17B13-IN-99 to explore therapeutic strategies and mechanisms related to these health issues. -
HSD17B13 Inhibitor
HSD17B13-IN-22 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates significant biological activity in modulating lipid metabolism and is relevant in the study of liver-related disorders, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Its application in research enables a deeper understanding of HSD17B13's role in these conditions, potentially paving the way for therapeutic advancements. -
HSD17B13 Inhibitor
HSD17B13-IN-60 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is primarily utilized in research related to liver and metabolic diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibition of HSD17B13 makes it a valuable tool for understanding the underlying mechanisms of these disorders and developing potential therapeutic strategies. -
17β-HSD Inhibitor
HSD17B13-IN-18 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for Leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), particularly in the study of nonalcoholic steatohepatitis (NASH). HSD17B13-IN-18 facilitates research aimed at understanding and potentially therapeutically targeting metabolic disorders related to liver function. -
17β-HSD1 Inhibitor
3-Acetyl-7-Hydroxycoumarin is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). It exhibits significant biological activity, demonstrating 57% inhibition of 17β-HSD1 at a concentration of 6 μM. This compound is valuable for research applications focused on hormone-dependent diseases, including breast cancer and endometriosis. -
HSD17B13 Inhibitor
HSD17B13-IN-94 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in the investigation of liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 provides valuable insights into the underlying mechanisms of these diseases. -
HSD17B13 Inhbitor
HSD17B13-IN-78 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD), aiding in the understanding of lipid metabolism and associated metabolic disorders. HSD17B13-IN-78 serves as an important tool for studying the therapeutic potential of targeting HSD17B13 in liver-related pathologies. -
AKR1C3 Inhibitor
S07-2005 (racemic) is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor, exhibiting an IC50 value of 0.13 μM for AKR1C3 and 0.75 μM for AKR1C4. This compound demonstrates significant potential as a chemotherapeutic potentiator, particularly in overcoming resistance mechanisms in cancer treatment. Its selectivity and efficacy make it a valuable tool for research applications focused on cancer biology and drug resistance mechanisms. -
HSD17B13 Inhibitor
HSD17B13-IN-56-d3 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action makes it a significant tool for exploring therapeutic strategies targeting these conditions. -
17β-HSD Inhibitor
HSD17B13-IN-36 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol as a substrate. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH), making it valuable for research concerning metabolic disorders and liver health. Its selective inhibition of HSD17B13 may provide insights into therapeutic interventions for liver-related diseases. -
HSD17B13 Inhbitor
HSD17B13-IN-85 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily employed in the study of nonalcoholic fatty liver disease (NAFLD) and offers significant insights into the role of HSD17B13 in metabolic regulation and liver physiology. Its specific inhibition enhances understanding of the enzyme's contribution to various biological processes and potential therapeutic targets in liver-related disorders. -
FXR/HSD17B13 Modulator
FXR/HSD17B13 modulator 1 is a potent modulator targeting the farnesoid X receptor (FXR) and hydroxysteroid dehydrogenase 17 beta 13 (HSD17B13). This compound demonstrates significant biological activity relevant to the study of metabolic dysfunction-associated steatohepatitis (MASH). Its modulation of these targets can provide insights into therapeutic strategies for liver-related metabolic disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-84 is a potent inhibitor of the enzyme 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research concerning nonalcoholic fatty liver disease (NAFLD), providing valuable insights into the role of HSD17B13 in lipid metabolism and liver pathophysiology. Its effective inhibition of HSD17B13 supports studies aimed at understanding disease mechanisms and potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-98 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), demonstrating an IC50 value for estradiol of less than 0.1 μM. This compound is particularly relevant in the investigation of nonalcoholic fatty liver disease, providing valuable insights into the biochemical pathways involved in lipid metabolism and liver function. Its specificity and efficacy make it an essential tool for research focused on metabolic disorders and related therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-59 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specific mechanism of action makes it an essential tool in elucidating the role of HSD17B13 in various pathophysiological contexts. -
17β-HSD1 Inhibitor
7-Coumaryl triflate is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), demonstrating an IC₅₀ of 360 nM and a Kᵢ of 173 nM. This compound selectively targets 17β-HSD2 while displaying no significant affinity for estrogen receptors ERα or ERβ. 7-Coumaryl triflate is valuable for research focused on hormone-dependent breast cancer and the modulation of estrogen metabolism. -
HSD17B13 Inhibitor
HSD17B13-IN-26 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound exhibits significant activity in the modulation of steroid metabolism and demonstrates potential therapeutic applications in liver diseases, including hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. Researchers can utilize HSD17B13-IN-26 to further investigate the role of HSD17B13 in liver pathology and associated metabolic disorders.
